Sun Pharmaceutical Industries Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Classic ViewEnhanced View

Sun Pharmaceutical Industries Share Price

1,703.35-31.36 (-1.81%)

Live
As On: 01 Apr, 2025, 10:48 AM IST
As On: 01 Apr, 2025, 10:48 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	1,731.00
High	1,733.95
Low	1,700.85
Prev Close	1,734.70
Volume	15,20,891
VWAP(?)	1,717.74

Stock Recommendations
- Potential Upside
- 1 Year Target
BUY
Mean Recos by 31 Analysts
0
2
4
12
13
Strong Sell
Sell
Hold
Buy
Strong Buy
Unlock Potential Upside
Stock Reports Plus
/10
Stock Score
View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Sun Pharma share price insights

Rank 60 - ET 5002023 ranking

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Stock Returns vs Nifty 100
Stock gave a 3 year return of 89.64% as compared to Nifty 100 which gave a return of 36.22%. (as of last trading session)
Stock Returns vs Nifty Pharma
Stock generated 89.64% return as compared to Nifty Pharma which gave investors 55.6% return over 3 year time period. (as of last trading session)
Sun Pharma Share Price Update
Sun Pharmaceutical Industries Ltd. share price moved down by -1.81% from its previous close of Rs 1,734.70. Sun Pharmaceutical Industries Ltd. stock last traded price is 1,703.40
Share Price Value
Today/Current/Last 1,703.401,704.30
Previous Day 1,734.701,735.45

Found Insights useful?

Sun Pharma Share Price Returns

1 Day	-1.81%
1 Month	6.91%
3 Months	-9.87%
1 Year	4.55%
3 Years	87.45%
5 Years	395.81%

Key Metrics

PE Ratio(x)	35.73
EPS - TTM(?)	47.69
MCap(? Cr.)	4,12,181
MCap Rank	1
PB Ratio(x)	6.20
Div Yield(%)	0.79
Face Value(?)	1.00
52W High(?)	1,960.35
52W Low(?)	1,377.20
MCap/Sales	8.02
Beta(1 Month)	-
BV/Share(?)	279.69

Sun Pharma Share Recommendations

Mean recosCurrent

BUY

31 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	13	13	12	11
Buy	12	12	13	12
Hold	4	4	5	7
Sell	2	2	2	3
Strong Sell	-	-	-	-
# Analysts	31	31	32	33

Recent Recos

Target₹1895
OrganizationICICI Securities
BUY

Target₹2115
OrganizationJM Financial
BUY

Target₹2094
OrganizationJM Financial
BUY

View all Stock Recommendations

Sun Pharma News & Analysis

View all Sun Pharma Share News & Announcements

Sun Pharma Financials

Management View (MD&A)
- Digital technologies - In post covid world, will it or will it not
  Digital technologies are being leveraged significantly for patient-to-doctor connect currently since a face-to-face consultation may not be possible due to COVID-19. It remains to be seen if this trend will continue in the post COVID-19 period also.
- Increasing overall market size but pricing pressure might continue
  Pharmaceutical spending in the top five Western European (WE5) markets is projected to grow at about 3-6% CAGR to US$210-240 Billion by 2024. Launch of new-age specialty products will drive this growth. Government led price control initiatives to improve patient access is likely to act as a counter-balancing force to this growth.
- Indian pharma industry has some inherent strength
  India is uniquely positioned as a crucial supplier of pharmaceuticals by way of chemistry expertise, lower personnel costs and the ability to manufacture quality medicines in compliance with global regulatory standards. It will continue to be an important player in the global generics market.

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Income	14,141.08	13,645.39	13,185.30	12,588.84	12,630.90
Total Income Growth (%)	3.63	3.49	4.74	-0.33	1.16
Total Expenses	10,613.17	9,978.34	9,700.26	9,699.75	9,595.82
Total Expenses Growth (%)	6.36	2.87	0.01	1.08	-0.52
EBIT	3,527.91	3,667.05	3,485.04	2,889.09	3,035.08
EBIT Growth (%)	-3.79	5.22	20.63	-4.81	6.86
Profit after Tax (PAT)	2,912.98	3,040.16	2,835.62	2,654.58	2,523.75
PAT Growth (%)	-4.18	7.21	6.82	5.18	6.24
EBIT Margin (%)	24.95	26.87	26.43	22.95	24.03
Net Profit Margin (%)	20.60	22.28	21.51	21.09	19.98
Basic EPS (?)	12.10	12.70	11.80	11.10	10.50

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Income	6,260.20	5,214.01	4,580.81	5,758.02	5,150.55
Total Income Growth (%)	20.06	13.82	-20.44	11.79	-1.00
Total Expenses	4,779.31	4,074.62	4,106.81	4,138.65	4,184.16
Total Expenses Growth (%)	17.29	-0.78	-0.77	-1.09	1.99
EBIT	1,480.89	1,139.39	474.00	1,619.37	966.39
EBIT Growth (%)	29.97	140.38	-70.73	67.57	-12.16
Profit after Tax (PAT)	1,181.05	863.29	237.82	867.60	721.31
PAT Growth (%)	36.81	263.00	-72.59	20.28	-18.83
EBIT Margin (%)	23.66	21.85	10.35	28.12	18.76
Net Profit Margin (%)	18.87	16.56	5.19	15.07	14.00
Basic EPS (?)	4.90	3.60	1.00	3.60	3.00

	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	49,851.04	44,520.20	39,576.00	34,333.66	33,473.48
Total Revenue Growth (%)	11.97	12.49	15.27	2.57	11.24
Total Expenses	38,268.83	34,940.32	30,527.86	27,228.15	28,203.25
Total Expenses Growth (%)	9.53	14.45	12.12	-3.46	12.51
Profit after Tax (PAT)	9,576.38	8,473.58	3,272.73	2,903.82	3,764.93
PAT Growth (%)	13.01	158.91	12.70	-22.87	41.25
Operating Profit Margin (%)	24.37	22.22	23.73	21.63	16.97
Net Profit Margin (%)	19.74	19.30	8.46	8.66	11.46
Basic EPS (?)	39.90	35.30	13.60	12.10	15.70

	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	20,740.93	21,091.17	16,543.90	12,953.43	14,042.85
Total Revenue Growth (%)	-1.66	27.49	27.72	-7.76	21.32
Total Expenses	17,072.26	16,412.33	14,416.51	10,711.00	10,789.85
Total Expenses Growth (%)	4.02	13.84	34.60	-0.73	11.92
Profit after Tax (PAT)	2,858.18	1,690.72	-99.99	2,139.70	3,211.14
PAT Growth (%)	69.05	-	-104.67	-33.37	293.23
Operating Profit Margin (%)	21.96	24.75	16.13	19.52	29.21
Net Profit Margin (%)	14.09	8.12	-0.64	16.71	25.62
Basic EPS (?)	11.90	7.00	-0.40	8.92	13.40

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Assets	85,462.88	80,743.59	69,799.87	67,666.73	68,252.46
Total Assets Growth (%)	5.84	15.68	3.15	-0.86	5.50
Total Liabilities	18,356.91	21,428.12	18,733.76	18,186.90	19,127.77
Total Liabilities Growth (%)	-14.33	14.38	3.01	-4.92	-4.22
Total Equity	67,105.97	59,315.47	51,066.11	49,479.83	49,124.69
Total Equity Growth (%)	13.13	16.15	3.21	0.72	9.84
Current Ratio (x)	2.56	2.00	2.04	1.89	2.02
Total Debt to Equity (x)	0.04	0.11	0.02	0.07	0.17
Contingent Liabilities	6,343.60	7,903.07	6,756.55	7,057.73	7,508.95

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Assets	41,064.79	40,987.49	40,765.48	38,998.83	38,410.33
Total Assets Growth (%)	0.19	0.54	4.53	1.53	1.85
Total Liabilities	17,370.39	17,239.13	16,177.53	13,958.67	14,014.11
Total Liabilities Growth (%)	0.76	6.56	15.90	-0.40	-5.76
Total Equity	23,694.40	23,748.36	24,587.95	25,040.16	24,396.22
Total Equity Growth (%)	-0.23	-3.41	-1.81	2.64	6.80
Current Ratio (x)	3.36	1.97	0.96	1.45	1.07
Total Debt to Equity (x)	0.47	0.32	0.20	0.26	0.24
Contingent Liabilities	2,013.74	4,309.60	3,811.82	3,564.25	3,863.62

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash flow from Operating Activities	12,134.98	4,959.33	8,984.54	6,170.37	6,554.77
Net Cash used in Investing Activities	-690.20	-7,943.68	-5,724.74	536.22	-2,588.84
Net Cash flow from Financing Activities	-6,710.16	2,376.07	-5,193.46	-5,980.48	-5,715.14
Net Cash Flow	4,661.92	115.48	-1,764.78	596.42	-1,385.69
Closing Cash & Cash Equivalent	9,285.65	4,623.73	4,508.25	6,273.03	5,676.61
Closing Cash & Cash Equivalent Growth (%)	100.83	2.56	-28.13	10.51	-19.62
Total Debt/ CFO (x)	0.23	1.25	0.10	0.54	1.16

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash flow from Operating Activities	-292.42	507.08	7,636.36	1,737.25	1,305.85
Net Cash used in Investing Activities	-262.91	-705.17	-2,702.10	-601.80	1,479.29
Net Cash flow from Financing Activities	473.95	169.31	-4,870.85	-1,126.29	-2,871.15
Net Cash Flow	-83.82	-9.25	68.47	1.84	-82.26
Closing Cash & Cash Equivalent	326.46	410.28	419.53	222.34	220.50
Closing Cash & Cash Equivalent Growth (%)	-20.43	-2.20	88.69	0.83	-27.17
Total Debt/ CFO (x)	-37.78	14.97	0.64	3.73	4.40

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 690.2 cr for investing activities which is an YoY decrease of 91.31%. (Source: Consolidated Financials)

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Return on Equity (%)	15.04	15.13	6.81	6.24	8.31
Return on Capital Employed (%)	17.26	16.02	17.44	14.06	10.60
Return on Assets (%)	11.20	10.49	4.68	4.29	5.51
Interest Coverage Ratio (x)	60.29	71.40	88.88	65.95	25.19
Asset Turnover Ratio (x)	0.58	0.58	0.56	0.49	0.49
Price to Earnings (x)	40.65	27.86	67.11	49.50	22.47
Price to Book (x)	6.11	4.21	4.57	3.09	1.87
EV/EBITDA (x)	26.75	19.51	19.30	15.36	11.73
EBITDA Margin (%)	29.64	27.98	29.28	27.84	23.22

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Return on Equity (%)	12.06	7.11	-0.40	8.54	13.16
Return on Capital Employed (%)	12.15	15.79	8.20	8.15	13.45
Return on Assets (%)	6.96	4.12	-0.24	5.48	8.36
Interest Coverage Ratio (x)	7.72	14.30	9.96	12.01	10.35
Asset Turnover Ratio (x)	0.49	0.51	0.39	0.33	0.33
Price to Earnings (x)	136.99	140.85	-2,500.00	67.11	26.32
Price to Book (x)	16.41	9.93	8.93	5.73	3.46
EV/EBITDA (x)	66.00	36.00	57.90	48.49	21.22
EBITDA Margin (%)	29.85	32.44	24.80	24.10	33.69

Found Financials useful?

Sun Pharma Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Sun Pharma Technicals

Buy/Sell Signals
10 Day EMA Crossover
Bearish signal on daily chart
Appeared on: 27 Mar 2025
10D EMA: 1735.57
Last Signal 14 Feb 2025 (Loss -4.03%)
Average price decline of -1.99% within 7 days of Bearish signal in last 5 years
Price Analysis
47%
Positive Movement
since 1st Jan 2005
on basis
53%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 1748.97 Pivot
1727.08
S1 1712.82
R2 1763.23 S2 1690.93
R3 1799.38 S3 1654.78
Average True Range
5 Days 14 Days 28 Days
36.01 38.08 39.15

Found Technicals useful?

Sun Pharma Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Sun Pharma	35.81	6.11	15.04	17.26	11.20	13.10	24.37	19.89	39.90	2.56	0.04	0.23
Divis Labs	74.35	11.32	11.78	15.26	10.34	5.13	27.60	20.39	60.27	7.57	0.00	0.00
Cipla	23.56	4.39	15.43	21.79	12.59	10.82	23.22	16.12	51.05	3.71	0.01	0.06
Torrent Pharma	58.11	15.78	24.15	27.16	10.99	10.08	24.39	15.44	48.94	1.03	0.57	1.21
Mankind Pharma	49.45	10.54	20.43	24.56	15.98	18.26	23.39	18.64	47.75	3.10	0.02	0.09
Add More

Annual Ratios (%)

Choose from Peers

Dr. Reddys
Lupin
Cadila Healthcare
Aurobindo Pharma
Alkem Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Insights

Stock Returns vs Nifty 100
Stock gave a 3 year return of 89.64% as compared to Nifty 100 which gave a return of 36.22%. (as of last trading session)
Stock Returns vs Nifty Pharma
Stock generated 89.64% return as compared to Nifty Pharma which gave investors 55.6% return over 3 year time period. (as of last trading session)

Found Peer Comparison useful?

Sun Pharma Shareholding Pattern

Total Shareholdings

Category	No. of Shares	Percentage	% Change QoQ
Promoters	1,30,71,34,535	54.48 %	0.00
Pledge	89,70,000	0.69 %	-0.10
FII	43,30,18,557	18.04 %	0.03
DII	44,02,48,080	18.35 %	-0.06
MF	29,36,20,857	12.24 %	0.13
Others	21,89,33,798	9.12 %	0.01

QoQ Change
Category Dec 2024 Sep 2024 Jun 2024 Mar 2024
Promoters 54.48 54.48 54.48 54.48
Pledge 0.69 0.79 1.07 2.05
FII 18.04 18.00 17.23 17.72
DII 18.35 18.41 19.08 18.65
Mutual Funds 12.24 12.11 12.78 12.21
Others 9.12 9.11 9.21 9.15

Mutual Funds Ownership

MF Ownership as on 28 February 2025

ICICI Pru Value Discovery Direct-G
Equity: Value Oriented
5.0
- 2,006.63
  Amount Invested (in Cr.)
- 4.35%
  % of AUM
- 0.00
  % Change (MoM basis)
ICICI Pru Bluechip Direct-G
Equity: Large Cap
5.0
- 1,631.34
  Amount Invested (in Cr.)
- 2.71%
  % of AUM
- 0.00
  % Change (MoM basis)
ICICI Pru Equity & Debt Direct-G
Hybrid: Aggressive Hybrid
5.0
- 1,605.27
  Amount Invested (in Cr.)
- 4.17%
  % of AUM
- 4.62
  % Change (MoM basis)

View all Mutual Fund Schemes

Sun Pharma Futures & Options

Type
Expiry Month
Strike Price

Date	Price	Open Interest
24-04-2025Current	43.35-8.00 (-15.58%)	1,15,5007,700 (7.14%)
48.95 Open	50.00 High	42.20 Low
51.35 Close	89 Contracts Traded	1,730.19 Turnover (? Lakhs)

Open Interest as of 01 Apr 2025

Expiry MonthPlease select expiry month:

Date	Price	Open Interest
24-04-2025Current	1,727.25-12.05 (-0.69%)	1,44,20,3502,12,150 (1.49%)
1,742.20 Open	1,742.20 High	1,721.10 Low
1,739.30 Prev Close	542 Contracts Traded	10,336.13 Turnover (? Lakhs)

Open Interest as of 01 Apr 2025

Sun Pharma Top Searches

Corporate Actions

Recent
General Meeting
-
Feb 20, 2025
Board Meeting
Quarterly Results & Interim Dividend
Jan 16, 2025
Interim Dividend
1050%
Jan 16, 2025

Announced on	Meeting on
Jan 16, 2025	Jan 31, 2025
Quarterly Results & Interim Dividend
Oct 09, 2024	Oct 28, 2024
Quarterly Results
Jul 15, 2024	Aug 01, 2024
Quarterly Results
May 13, 2024	May 22, 2024
Audited Results & Final Dividend
Jan 15, 2024	Jan 31, 2024
Quarterly Results & Interim Dividend

Dividends
Announced on Ex-Date Dividend%
Jan 16, 2025 Feb 06, 2025 1050%
May 22, 2024 Jul 12, 2024 500%
Jan 15, 2024 Feb 09, 2024 850%
Jul 07, 2023 Jul 28, 2023 400%
Jan 16, 2023 Feb 08, 2023 750%

Announced on	Ex-Date
May 28, 2013	Jul 29, 2013
Bonus Ratio: 1 share(s) for every 1 shares held
Apr 21, 2004	May 27, 2004
Bonus Ratio: 1 share(s) for every 1 shares held
Feb 09, 2000	Mar 06, 2000
Bonus Ratio: 2 share(s) for every 1 shares held

Splits
Announced on Ex-Date
Sep 24, 2010 Nov 25, 2010
Split: Old FV5.0| New FV:1.0
Oct 28, 2002 Jan 13, 2003
Split: Old FV10.0| New FV:5.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Feb 20, 2025 Mar 27, 2025
-
Dec 10, 2024 Jan 21, 2025
-
Jun 19, 2024 Aug 05, 2024
-
Jul 07, 2023 Aug 28, 2023
-
Aug 03, 2022 Aug 29, 2022
-

About Sun Pharma

Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 4,16,212.64 Crore) operating in Pharmaceuticals sector.

Sun Pharmaceutical Industries Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024.

For the quarter ended 31-12-2024, the company has reported a Consolidated Total Income of Rs 14,141.08 Crore, up 3.63 % from last quarter Total Income of Rs 13,645.39 Crore and up 11.96 % from last year same quarter Total Income of Rs 12,630.90 Crore. Company has reported net profit after tax of Rs 2,917.54 Crore in latest quarter.

The company’s top management includes Mr.Dilip S Shanghvi, Mr.Abhay Gandhi, Mr.S Damodharan, Dr.Uday Baldota, Mr.Aalok D Shanghvi, Mr.Sudhir V Valia, Mr.Gautam Doshi, Dr.Pawan Goenka, Mr.Rama Bijapurkar, Mr.Rolf Hoffmann, Mr.Sanjay Asher, Mr.C S Muralidharan, Mr.Anoop Deshpande. Company has S R B C & Co. LLP as its auditors. As on 31-12-2024, the company has a total of 239.93 Crore shares outstanding.

Sun Pharma Share Price Today is Rs. 1703.15. On previous day, the Sun Pharma Share Price (NSE) closed at Rs. 1731.45, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Dec, 2024, the promoter held 54.48% of the stake in Sun Pharma shares, out of which 0.69% was pledged. On the same date, foreign institutional investors' (FII) holdings of Sun Pharma stocks was 18.04% as compared to 18.01% in Sep 2024 with increase of 0.03%. The domestic institutional investors (DII) holdings on 31st Dec, 2024 was 18.35% as compared to 18.42% in Sep 2024 with decrease of 0.07%. Out of the total DII holdings in Sun Pharma shares 12.24% was held by mutual funds. The rest including public held is 9.13%. Sun Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Sun Pharma Dividend: Ever since 1993, Sun Pharma dividends has been paid out around 39 times. As on 01 Apr, 2025, 10:48 AM IST, The overall dividend yield for Sun Pharma stands at 0.78%. The last dividend paid was on February 6, 2025 (Rs. 10.5). The Earnings Per Share (EPS) for quarter ending 31st Dec 2024 is Rs. 47.69.

Sun Pharma Bonus: The most recent bonus issue had been in year July 29, 2013 around 11 years ago at 1 : 1 ratio. The first bonus issue was announced in Feb 2000.

Stock Forecast:
After showing 14379.6 Cr. of sales and 5.38% of quarterly net profit, there have been multiple ups and downs in the Sun Pharma stock prices in the past few weeks. For example, Sun Pharma stock price on 24th of March 2025 was around Rs. 1784.5. Sun Pharma share price now stands at an average of Rs. 1703.15. Judging by last week's performance, stock is in down trend.

Sun Pharma has a median target price of Rs. 2022.3 in 12 months by 33 analysts. They have provided a high estimate of Rs. 2450.0 and low estimate of Rs. 1475.0 for Sun Pharma share.

Historical Prices and Performance:
Sun Pharma, incorporated in 1993 is a Large Cap company (with a market cap of Rs. 416212.64) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Sun Pharma stock was 15.04%, 15.13%, 6.81%, 6.24% and 8.31% respectively.
The Sun Pharma share gave a 3 year return of 88.69% as compared to Nifty 50 which gave a return of 35.75%.
Sun Pharma announced 1050.0% final dividend on February 6, 2025.

Key Metrics:
PE Ratio of Sun Pharma is 36.37
Prices/Sales Ratio of Sun Pharma is 8.02
Price/Book Ratio of Sun Pharma is 6.2

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Sun Pharma, major competitors and peers include Divis Labs, Cipla, Torrent Pharma and Mankind Pharma. As of Sep 2024, the dividend yield of Sun Pharma stands at 0.78% while Divis Labs, Cipla, Torrent Pharma and Mankind Pharma stand at 0.52%, 0.9%, 0.87% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 36.37 and 6.2 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 31, Three months ago this number stood at 33. Out of total, 13 analyst have a'Strong Buy' reco, 12 analyst have a'Buy' reco, 4 analyst have a'Hold' reco, 2 analyst have a'Sell' reco.

Mean recommendations by 31 analyst stand at'Buy'.

Leadership of Sun Pharma :
Anoop Deshpande is Co. Secretary & Compl. Officer
C S Muralidharan is Chief Financial Officer
Abhay Gandhi is CEO - North America
Uday Baldota is CEO - Taro Pharmaceutical Industries Ltd.
Kirti Ganorkar is Head
Azadar H Khan is Head
Hellen de Kloet is Business Head
Sreenivas Rao is Head
S Damodharan is CEO - API Business
Suresh Rai is Chief Human Resource Officer
Meeta Chatterjee is Chief Strategy Officer
Dheeraj Sinha is Chief Information Officer
Marek Honczarenko is Head
Sridhar Shankar is Head
Dilip S Shanghvi is Chairman & Managing Director
Aalok D Shanghvi is Whole Time Director
Sudhir V Valia is Non Exe.Non Ind.Director
Pawan Goenka is Lead Independent Director
Rama Bijapurkar is Independent Director
Gautam Doshi is Independent Director
Sanjay Asher is Independent Director
Rolf Hoffmann is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty 50, BSE Sensex, Nifty 100, Nifty 200, Nifty 500

Address

Sun Pharma Advanced Research Centre (SPARC),Tandalja,Vadodra, Gujarat - 390012

Contact

secretarial@sunpharma.com

http://www.sunpharma.com

Executive Leadership

DS

Dilip S Shanghvi

Chairman & Managing Director

AG

Abhay Gandhi

CEO - North America

SD

S Damodharan

CEO - API Business

UB

Uday Baldota

CEO - Taro Pharmaceutical Industries Ltd.

Show More

Auditors

S R B C & Co. LLP

FAQs about Sun Pharma share

1. What's Sun Pharma share price today and what are Sun Pharma share returns ?
Sun Pharma share price is Rs 1,703.40 as on 01 Apr, 2025, 10:48 AM IST. Sun Pharma share price is down by 1.81% based on previous share price of Rs 1,731.45. Sun Pharma share price trend:
- Last 1 Month: Sun Pharma share price moved up by 6.91%
- Last 12 Months: Sun Pharma share price moved up 4.55%
- Last 3 Years: Sun Pharma Share price moved up by 87.45%
2. What are the key metrics to analyse Sun Pharma Share Price?
Sun Pharma share can be quickly analyzed on following metrics:
- Stock's PE is 35.73
- Price to Book Ratio of 6.20
3. What is the market cap of Sun Pharma?
Within the Pharmaceuticals sector, Sun Pharma stock has a market cap rank of 1. Sun Pharma has a market cap of Rs 4,12,182 Cr.
4. Who are the key owners of Sun Pharma stock?
5. What are the returns for Sun Pharma share?
Return Performance of Sun Pharma Shares:
- 1 Week: Sun Pharma share price moved down by 3.48%
- 1 Month: Sun Pharma share price moved up by 6.91%
6. What is the CAGR of Sun Pharma?
The CAGR of Sun Pharma is 9.69.
7. Which are the key peers to Sun Pharma?
Top 10 Peers for Sun Pharma are Divi's Laboratories Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mankind Pharma Ltd., Zydus Lifesciences Ltd., Lupin Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd. and Biocon Ltd.
8. What has been highest price of Sun Pharma share in last 52 weeks?
In last 52 weeks Sun Pharma share had a high price of Rs 1,960.35 and low price of Rs 1,377.20
9. Who is the Chief Executive Officer of Sun Pharma?
Abhay Gandhi is the CEO - North America of Sun Pharma
10. What are the Sun Pharma quarterly results?
Total Revenue and Earning for Sun Pharma for the year ending 2024-03-31 was Rs 49851.04 Cr and Rs 9576.38 Cr on Consolidated basis. Last Quarter 2024-12-31, Sun Pharma reported an income of Rs 14141.08 Cr and profit of Rs 2912.98 Cr.
11. What is the PE & PB ratio of Sun Pharma?
The PE ratio of Sun Pharma stands at 36.37, while the PB ratio is 6.2.
12. What dividend is Sun Pharma giving?
An equity Interim dividend of Rs 10.5 per share was declared by Sun Pharmaceutical Industries Ltd. on 16 Jan 2025. So, company has declared a dividend of 1050% on face value of Rs 1 per share. The ex dividend date was 06 Feb 2025.

Top Gainers

As on 10:46 AM | 01 Apr 2025

525.05

52.55 (11.13%)

7.48

0.69 (10.01%)

356.95

22.65 (6.78%)

Tata Teleservices

59.96

3.68 (6.52%)

809.85

49.40 (6.50%)

Top Losers

As on 10:42 AM | 01 Apr 2025

33.30

-2.41 (-6.73%)

1,535.75

-87.46 (-5.39%)

1,383.90

-74.80 (-5.13%)

1,083.40

-50.75 (-4.48%)

514.05

-22.16 (-4.14%)

Equity Quick Links

Top Gainers
Top Losers
Stock Recommendations
Stock Screener
Candlestick Screener
Upcoming Dividends
Volume Shockers
Hourly losers
Hourly gainers

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.